Thursday, April 24, 2014   

Shenzhen drug maker Biokangtai investigated following baby deaths
(12-24 13:59)

China has sent health experts to investigate a drug maker to establish if the deaths of several babies in recent weeks were related to vaccines they received in a government immunization program.
China Central Television said a team of government investigators had been sent to Biokangtai, a drug maker based in Shenzhen.
The company's hepatitis B vaccines have come under scrutiny since authorities suspended their use for liver disease after the first deaths of babies were reported.
Provincial and national health authorities have separately reported that since November about a half-dozen babies died shortly after they received hepatitis B vaccines made by Biokangtai.
One case has been ruled out as being caused by the vaccine while the others were still being investigated. –AP

   
Other China breaking news:
Water pollution serious in China: study (04-23 14:28)
Nine arrested for deadly mine blast (04-23 14:22)
Provincial official expelled from CPC (04-22 15:01)
Shandong Airlines orders 50 Boeing 737s (04-22 10:55)
Blogger jailed in online 'rumour' crackdown (04-17 12:22)
More dead pigs found in Qinghai river: report (04-17 12:14)
3 dead, 5 missing in Jiangsu chemical plant blast (04-16 18:12)
Mainland open to cross-Strait leaders summit (04-16 17:55)
Captain America tops China box office (04-15 19:06)
Tap water company denies pollution cover-up (04-15 13:15)

More breaking news >>

© 2014 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts

 


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2014, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.